Trending...
- Governor Newsom honors fallen California Highway Patrol Officer Miguel Cano
- Spartan & Guardians Partner with Guitar Legend Buckethead to Support Global Child Rescue Efforts
- Plan to Launch Silo Technologies' Cybersecurity Pilot Program for Ultimate Nationwide Deployment via Exclusive Partnership: Stock Symbol: BULT
LOS ANGELES - Californer -- A research team at UCLA has developed a deep learning-powered chemiluminescence vertical flow assay (CL-VFA) that brings clinical laboratory-grade cardiac troponin I (cTnI) testing to a portable, cost-effective point-of-care platform. Their work, recently published in the journal Small, demonstrates how the integration of chemiluminescence-based biosensing, high-sensitivity imaging through a portable reader, and AI-driven data analysis enables rapid, highly sensitive cTnI quantification for the detection of myocardial infarction (MI), also known as heart attack, in diverse clinical settings. This technology holds the potential to democratize access to fast and reliable cardiac diagnostics, particularly in resource-limited environments where advanced laboratory infrastructure is lacking.
This research was led by Dr. Aydogan Ozcan, Chancellor's Professor of Electrical & Computer Engineering and the associate director of the California NanoSystems Institute (CNSI) at UCLA, in collaboration with Professor Dino Di Carlo of the UCLA Bioengineering Department, Professor Omai Garner, the director of UCLA Clinical Microbiology Lab. The first authors of the paper are Dr. Gyeo-Re Han, a postdoctoral researcher, and Artem Goncharov, a graduate student at UCLA Electrical & Computer Engineering Department.
More on The Californer
This platform features a robust integration of deep learning-driven computational analysis and highly sensitive chemiluminescence biosensing. This innovation allows for the detection of cTnI at levels as low as 0.1-0.2 pg/mL and an extensive dynamic range from less than 1 pg/mL to 100 ng/mL. These specifications outperform existing point-of-care devices, effectively meeting the clinical standards for high-sensitivity troponin testing—an essential factor in early MI diagnosis and risk stratification. This point-of-care sensor requires only 50 µL of serum and features a streamlined workflow, potentially enabling medical staff to perform tests with simplicity. It provides cTnI results in just 25 min for rapid clinical decision-making.
The researchers rigorously validated their sensor platform using clinical serum samples. In a blinded validation study with patient samples, their sensor showed a strong correlation with an FDA-cleared laboratory analyzer, demonstrating its reliability, clinical accuracy, and potential for real-world diagnostic applications.
More on The Californer
Beyond its high performance, this sensor is also designed for affordability. Traditional benchtop chemiluminescence analyzers cost more than ~$10,000-20,000. In contrast, the UCLA reader system, which is built on a custom optical imager, costs ~$222, while each test is priced at ~$4. This cost-effectiveness of the sensor makes it an ideal solution for expanding access to cardiac diagnostics in primary care clinics, pharmacies, and mobile health units, particularly in resource-constrained settings.
This research was supported by the NSF-funded Precise Advanced Technologies and Health Systems for Underserved Populations (PATHS-UP) Engineering Research Center (ERC).
Link to the Article: https://onlinelibrary.wiley.com/doi/10.1002/smll.202411585
This research was led by Dr. Aydogan Ozcan, Chancellor's Professor of Electrical & Computer Engineering and the associate director of the California NanoSystems Institute (CNSI) at UCLA, in collaboration with Professor Dino Di Carlo of the UCLA Bioengineering Department, Professor Omai Garner, the director of UCLA Clinical Microbiology Lab. The first authors of the paper are Dr. Gyeo-Re Han, a postdoctoral researcher, and Artem Goncharov, a graduate student at UCLA Electrical & Computer Engineering Department.
More on The Californer
- Luxury Auto Detailing Brings High-End Mobile Car Care to Cherry Valley and Surrounding Areas
- Transgender Visual Artist Debuts New Work
- Stay Cool All Day With BGMgirl Drawstring Half Wigs
- California: Governor Newsom proclaims Independence Day 2025
- Gundam GQuuuuuuX Takes Center Stage at Anime Expo 2025
This platform features a robust integration of deep learning-driven computational analysis and highly sensitive chemiluminescence biosensing. This innovation allows for the detection of cTnI at levels as low as 0.1-0.2 pg/mL and an extensive dynamic range from less than 1 pg/mL to 100 ng/mL. These specifications outperform existing point-of-care devices, effectively meeting the clinical standards for high-sensitivity troponin testing—an essential factor in early MI diagnosis and risk stratification. This point-of-care sensor requires only 50 µL of serum and features a streamlined workflow, potentially enabling medical staff to perform tests with simplicity. It provides cTnI results in just 25 min for rapid clinical decision-making.
The researchers rigorously validated their sensor platform using clinical serum samples. In a blinded validation study with patient samples, their sensor showed a strong correlation with an FDA-cleared laboratory analyzer, demonstrating its reliability, clinical accuracy, and potential for real-world diagnostic applications.
More on The Californer
- John Duffy Competes in Mr Muscle Beach
- New Release: 'The Invisible Alternative' Unveiled by Atrisk Corporation, Resilient
- Thorn & Bloom Magazine Unveils Groundbreaking Second Edition: "Breaking the Cycle"
- Cheap O SMS Launches Groundbreaking Free SMS API Service
- California: Governor Newsom signs legislation 7.3.25
Beyond its high performance, this sensor is also designed for affordability. Traditional benchtop chemiluminescence analyzers cost more than ~$10,000-20,000. In contrast, the UCLA reader system, which is built on a custom optical imager, costs ~$222, while each test is priced at ~$4. This cost-effectiveness of the sensor makes it an ideal solution for expanding access to cardiac diagnostics in primary care clinics, pharmacies, and mobile health units, particularly in resource-constrained settings.
This research was supported by the NSF-funded Precise Advanced Technologies and Health Systems for Underserved Populations (PATHS-UP) Engineering Research Center (ERC).
Link to the Article: https://onlinelibrary.wiley.com/doi/10.1002/smll.202411585
Source: ucla ita
Filed Under: Health
0 Comments
Latest on The Californer
- Porta Potty USA Expands its Convenient Portable Restroom Rental Services Business in Montana Area
- A Shepherd's Legacy: Honoring the Life and Impact of Pastor Ross Reinman
- California: Here's how President Trump's tax cuts for the ultra-rich will hurt YOU
- New Media Film Festival Announces Winners
- New Podcast "Spreading the Good BUZZ" Hosted by Josh and Heidi Case Launches July 7th with Explosive Global Reach and a Mission to Transform Lives
- DetailAxis Unveils it's 'Business Engine': Powerful AI Systems for Auto Appearance Pros
- California: Governor Newsom announces appointments 7.2.25
- The Herbal Care, Led by Markel Bababekov, Becomes a Top Dispensary in NYC's Upper East Side
- Digital Watchdog Launches New myDW Cloud Services
- Governor Newsom honors fallen California Highway Patrol Officer Miguel Cano
- Stan Fitzgerald Appointed Acting Press Secretary for Veterans for America First VFAF Georgia State Chapter
- Drone Light Shows Emerge as the New Standard in Live Event Entertainment
- Lore Link is Here to Help Organize Your Game
- Governor Newsom marks historic expansion of California's Film and Television Tax Credit Program, announces 16 new projects to film in the Golden State
- Talar Guedikian Named Winner of 2025 AAJ Paralegal of the Year Award, Sponsored by Advocate Capital
- Chappaqua's Annual Townwide Summer Sale – Unbeatable Savings at Your Favorite Local Boutiques!
- Skyline Partners with ZenSpace to Offer Private Meeting Pods for Trade Show Exhibitors
- California: Did gas prices go up by 65 cents at the pump? No.
- Snell & Wilmer Welcomes Associate Victoria Cendejas to the Orange County Office
- Crime in California drops again — state records second-lowest homicide rate since 1966